Hansen Gwenn's Form 4 filing
Nurix Therapeutics, Inc. (NRIX) · filed Aug 5, 2026
- Accession no.
- 0001817160-26-000015
- Filed
- Aug 5, 2026, 6:39 AM ET
- Trade date
- Aug 4, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $100.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hansen GwennCIK 0001817160 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.38. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price. The lowest price at which shares were sold was $24.43 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.